Last reviewed · How we verify
Potassium Canrenoate
Potassium Canrenoate is a Small molecule drug developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. It is currently in Phase 2 development. Also known as: Canrenone.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Potassium Canrenoate |
|---|---|
| Also known as | Canrenone |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial (PHASE2)
- Spironolactone Therapy In Young Women With NASH (PHASE1, PHASE2)
- Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women (PHASE1)
- Spironolactone for Hidradenitis Suppurativa (PHASE4)
- Spironolactone for the Treatment of Melasma (PHASE1)
- Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment (PHASE3)
- A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Potassium Canrenoate CI brief — competitive landscape report
- Potassium Canrenoate updates RSS · CI watch RSS
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico portfolio CI
Frequently asked questions about Potassium Canrenoate
What is Potassium Canrenoate?
Who makes Potassium Canrenoate?
Is Potassium Canrenoate also known as anything else?
What development phase is Potassium Canrenoate in?
Related
- Manufacturer: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico — full pipeline
- Also known as: Canrenone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing